Drug Type Protein drugs |
Synonyms |
Target |
Mechanism INF-λ1 modulators(interferon lambda 1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Phase 2 | CN | 20 Apr 2023 | |
COVID-19 | Phase 1 | AR | 30 Oct 2021 | |
Pulmonary Fibrosis | Phase 1 | CN | 06 Feb 2021 | |
COVID-19 | Preclinical | PE | 30 Oct 2021 | |
COVID-19 | Preclinical | AR | 30 Oct 2021 | |
COVID-19 | Preclinical | PE | 30 Oct 2021 |